These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 23252359)

  • 1. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.
    Becker R; Dembek C; White LA; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):775-93. PubMed ID: 23252359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent development of poly(ethylene glycol)-cholesterol conjugates as drug delivery systems.
    He ZY; Chu BY; Wei XW; Li J; Edwards CK; Song XR; He G; Xie YM; Wei YQ; Qian ZY
    Int J Pharm; 2014 Jul; 469(1):168-78. PubMed ID: 24768727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEG - a versatile conjugating ligand for drugs and drug delivery systems.
    Kolate A; Baradia D; Patil S; Vhora I; Kore G; Misra A
    J Control Release; 2014 Oct; 192():67-81. PubMed ID: 24997275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The price of success: cost-effectiveness of molecularly targeted agents.
    Sleijfer S; Verweij J
    Clin Pharmacol Ther; 2009 Feb; 85(2):136-8. PubMed ID: 19151639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs.
    Zolnik BS; Sadrieh N
    Adv Drug Deliv Rev; 2009 Jun; 61(6):422-7. PubMed ID: 19389437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population.
    Migeon-Duballet I; Chabin M; Gautier A; Mistouflet T; Bonnet M; Aubert JM; Halphen M
    Curr Med Res Opin; 2006 Jun; 22(6):1227-35. PubMed ID: 16846556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
    Turecek PL; Bossard MJ; Schoetens F; Ivens IA
    J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ; Carter JA; Kaura S; Botteman MF
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis.
    Sullivan PW; Follin SL; Nichol MB
    Med Care; 2003 Dec; 41(12):1382-95. PubMed ID: 14668671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
    Fishburn CS
    J Pharm Sci; 2008 Oct; 97(10):4167-83. PubMed ID: 18200508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
    Falagas ME; Fragoulis KN; Karydis I
    PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective drug delivery by PEGylated drug conjugates.
    Greenwald RB; Choe YH; McGuire J; Conover CD
    Adv Drug Deliv Rev; 2003 Feb; 55(2):217-50. PubMed ID: 12564978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic transdermal drug innovation from 2000 to 2014: current status and outlook.
    Walter JR; Xu S
    Drug Discov Today; 2015 Nov; 20(11):1293-9. PubMed ID: 26116094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.